Suven Life Sciences Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated total income of ₹829.79 Lakhs for the quarter, reflecting a significant growth compared to both the previous quarter and the corresponding quarter of the last year. However, the company continues to report a net loss of ₹1,116.73 Lakhs for the quarter, primarily due to sustained high investment in Research & Development (R&D) activities.

Suven Life Sciences is a biopharmaceutical company headquartered in Hyderabad, India, specialized in the discovery and development of New Chemical Entities (NCEs). The company’s core business focuses on Central Nervous System (CNS) disorders, targeting unmet medical needs through a robust clinical development pipeline that includes candidates for Alzheimer’s disease, Major Depressive Disorder (MDD), and Narcolepsy. During 2025, Suven reached a critical 50% patient enrollment milestone in its Global Phase-3 clinical trial for Masupirdine (SUVN-502) and initiated a Phase-2b trial for Ropanicant in the USA. As a research-driven entity, the company manages extensive intellectual property, having been granted 7 patents during the most recent reporting period across multiple global jurisdictions.